Clinical Trial

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Study acronym: CAPTIVA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Protocol Amendment History 5 changes
notable Trial sites reduced: 117 -> 114 locations 2026-05-15
notable Primary completion pushed: 2027-01 -> 2027-01-31 2026-05-09
minor Completion pushed: 2027-01 -> 2027-01-31 2026-05-09
notable Primary completion moved earlier: 2028-05-31 -> 2027-01 2026-04-16
minor Completion moved earlier: 2028-05-31 -> 2027-01 2026-04-16
Trial Details
NCT Number NCT05047172
Lead Sponsor University of Florida
Collaborators: National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Conditions Intracranial Arteriosclerosis, Stroke
Enrollment 1,683 participants
Start Date 2022-08-02
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10